ArticlePostgraduate medical journal1995
Soluble interleukin-2 receptor in patients with glomerular diseases.
Article in Postgraduate medical journal, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 9 citations in OpenAlex.
- Role of the adaptive immune system in diabetic kidney disease.Journal of diabetes investigation · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we measured the soluble interleukin-2 receptor (sIL-2R) level to evaluate the cellular immune status in 61 patients with different types of glomerular diseases; 40 healthy volunteers were used as control. All patients with glomerular diseases had levels of serum sIL-2R significantly higher than those of the controls (766 +/- 59 vs 280 +/- 23 U/ml; p < 0.05). Even patients with normal renal function still had higher serum sIL-2R levels than the controls, no matter to which subgroups they belonged (primary glomerulonephritis, lupus nephritis or diabetic nephropathy). Serum sIL-2R levels were similar among the three subgroups. The serum levels of sIL-2R correlated well with age and were significantly higher in older patients, although this was not observed in the control group. Serum sIL-2R levels were significantly higher in patients with active urinary sediment and in patients with impaired renal function and showed a significant negative correlation with creatinine clearance (r = -0.56; p < 0.05). Although urinary and serum sIL-2R levels were quite well correlated, (r = 0.35; p < 0.05), the urinary levels of sIL-2R did not differ in patients with different disease activity or different renal functions although they had a significant correlation with 24-hour urinary protein (r = 0.39; p < 0.05). Patients with nephrotic syndrome also had higher urinary sIL-2R levels than other patients (529 +/- 106 vs 280 +/- 31 U/ml; p < 0.05). We conclude that greater T-cell activation might contribute to the pathogenesis of different glomerulonephritis entities, and serum levels of sIL-2R can serve as a useful clinical marker of glomerulonephritis activity. Renal function influenced the serum levels of sIL-2R significantly. This factor must be considered when we interpret the data. Urinary sIL-2R levels did not reflect the disease activity as well. This might be due to the secondary influence of the extent of the glomerular protein leak. Further investigation is needed to define the exact excretory pathway of this substance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.